LA POSIBLE AMENAZA DE LA DISFUNCIÓN RENAL

Las enfermedades renales agudas y crónicas son frecuentes después de un TCMH y pueden tener efectos a largo plazo e impactos negativos en la mortalidad y la morbilidad. La lesión renal asociada al TCMH puede ser multifactorial, con causas que incluyen quimioterapia de acondicionamiento, radiación, medicamentos nefrotóxicos y EICH.18 Para complicar aún más el tratamiento, a menudo es necesario realizar ajustes en la dosis de antivirales en caso de insuficiencia renal.12,19 Esto genera el difícil acto de equilibrio entre el manejo del CMV y la disfunción renal.

UN CICLO PELIGROSO QUE AUMENTA EL RIESGO DE RESISTENCIA

El acto de equilibrar la nefrotoxicidad es complicado, ya que se debe controlar la función renal y a menudo se realizan ajustes de dosis en caso de disfunción renal.5 Sin embargo, la misma dosis reducida que puede ayudar a proteger los riñones es un factor de riesgo de resistencia, lo que a su vez hace que la infección por CMV sea más difícil de tratar satisfactoriamente.20

  1. Niederwieser D, Baldomero H, Atsuta Y, et al. One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Blood 2019;134(Supplement 1):2035.
  2. Haematopoietic Stem Cell Treatment HSCtx. World Health Organization. Accessed August 10, 2020. https://www.who.int/transplantation/hsctx/en/
  3. Cho S, Lee D, Kim H. Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy. Int J Mol Sci. 2019;20(11):2666.
  4. Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360-4367.
  5. Boeckh M, Ljungman P. How I treat cytomegalovirus in hematopoietic cell transplant Recipients. Blood. 2009;113(23):5711-5719.
  6. Camargo JF, Komanduri KV. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10(4):233-238.
  7. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients. Hematol Oncol Stem Cell Ther. 2011;25(1):151-169.
  8. Camargo JF, Kimble E, Rosa R, et al. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2018;24(4):806-814.
  9. Bar M, Flowers MED. Special Considerations for Long-Term Survivors After Hematopoietic Stem Cell Transplantation. In Ljungman P, Snydman D, Boeckh M. Transplant Infections. Springer International Publishing Switzerland; 2016:951-962.
  10. Chemaly RF, Chou S, Einsele H, et al. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis. 2019;68(8):1420-1426.
  11. Liu J, Kong J, Chang YJ, et al. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality. Clin Microbiol Infect. 2015;21(12):1121.e9-15.
  12. Avery RK, Arav-Boger R, Marr KA, et al. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. Transplantation. 2016;100(10):e74-e80.
  13. Solak Y, Biyik Z, Cizmecioglu A, et al. Cytomegalovirus and Aspergillus spp. coinfection in organ transplantation: a case report and review of the literature. CEN Case Rep. 2013;2(1):59-67.
  14. Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters. Blood Rev. 2017;31(3):173-183.
  15. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in Allogeneic Marrow Transplant Recipients Receiving Ganciclovir for Prevention of Cytomegalovirus Disease: Risk Factors and Outcome. Blood. 1997;90(6):2502-2508.
  16. Gooptu M, Koreth J. Better acute graft-versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect? Haematologica. 2017;102(5):806-808.
  17. Bashley A, Zhang X, Morris L, et al. Improved Survival of Patients Diagnosed with Severe (Grade3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to. Historic Controls. Blood. 2019;134(Supplement 1):2006.
  18. Angelo JR, Hingorani S. Chapter 9: Hematopoietic Stem Cell Transplant—Related Kidney Disease. In Perazella MA. Onco-Nephrology Curriculum. American Society of Nephrology; 2016:1-7. Accessed August 12, 2020. https://www.asn-online.org/education/distancelearning/curricula/onco/
  19. Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900-931.
  20. Drew WL. Cytomegalovirus Resistance Testing: Pitfalls and Problems for the Clinician. Clin Infect Dis. 2010;50(5):733-6.

Sitio destinado a profesionales de la salud fuera de Takedapro Argentina

¿Es Ud un profesional de la Salud?

No

Si